SCHEDULE: Lynx1 Proposes $5.20/Share Cash Acquisition of Neuphoria

Lynx1 Capital Management LP has proposed to acquire all outstanding shares of Neuphoria Therapeutics Inc. for $5.20 per share in cash, representing a 27% premium.

Summary

• Lynx1 Capital Management LP and Weston Nichols (Reporting Persons) beneficially own 875,328 shares of Neuphoria Therapeutics Inc. Common Stock, representing 26.5% of the outstanding class.
• On November 9, 2025, the Reporting Persons delivered a nomination notice to Neuphoria Therapeutics Inc. for two independent candidates, Kimberly Smith and Stephen Doberstein, to be elected as Class I directors at the upcoming annual meeting on December 9, 2025.
• On November 10, 2025, the Reporting Persons delivered a non-binding proposal to acquire all outstanding shares of Neuphoria Therapeutics Inc. for $5.20 per share in cash.
• The proposed acquisition price of $5.20 per share represents a premium of approximately 27% over the $4.10 closing stock price on Nasdaq on November 7, 2025.
• The proposal is based on assumptions including approximately $19 million in unrestricted cash at closing (net of estimated wind-down costs) and 3,298,042 shares outstanding.
• The offer price may be reduced if delays in consummating the transaction result in a reduction of the net unrestricted cash on the Company's balance sheet.
• Lynx1 has sufficient capital available to fund the acquisition, and financing will not be a condition for closing.
• The proposal is non-binding, and there is no assurance that any agreement will be reached or that the terms will not differ from the proposal.
• Lynx1 requested confidentiality regarding discussions and stated that disclosure or leaks could result in withdrawal of interest.
• Lynx1 is a multi-stage investment firm specializing in biotechnology, life sciences, and medical technology, with deep expertise in neuroscience.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant acquisition proposal offering a substantial premium to shareholders, backed by stated financial readiness from the acquirer. However, the non-binding nature and potential for price reduction due to delays introduce some caution.

Positives

• The proposal offers a significant premium of approximately 27% over the Company's recent closing stock price, potentially providing immediate value to shareholders.
• Lynx1 has stated it has sufficient capital available to fund the acquisition, indicating financial readiness and reducing financing risk.
• The proposal includes a nomination of two independent directors, which could enhance corporate governance and shareholder representation.

Negatives

• The proposal is non-binding and does not create a binding obligation, meaning there is no guarantee the transaction will be completed.
• The offer price is subject to reduction if delays in closing lead to a decrease in the Company's net unrestricted cash.
• Lynx1 explicitly stated that disclosure of discussions or leaks could result in the withdrawal of their interest in the acquisition.
• The proposal is based on certain assumptions about the Company's cash balance and share count, which could change.

Risks

• The non-binding nature of the proposal means there is no assurance that a definitive agreement will be reached or that the transaction will be consummated.
• Delays in the acquisition process could lead to a reduction in the proposed offer price if the Company's net unrestricted cash decreases.
• Lynx1 may change the terms of the proposal, accelerate or terminate discussions, or withdraw the proposal at any time without prior notice.
• The proposal is not an offer to buy or a solicitation of an offer to sell any of the Company's securities.

Future Outlook

Lynx1 Capital Management LP intends to engage in discussions with Neuphoria Therapeutics Inc. regarding the terms of the proposed acquisition. They may change the terms, accelerate or terminate discussions, withdraw the proposal, or take other actions to support their investment. The Reporting Persons may also engage with other stockholders, potential financing sources, and advisors to further the proposed transaction.

Management Comments

• "We are pleased to submit this non-binding indication of interest related to the potential acquisition of Neuphoria Therapeutics Inc."
• "Our proposal above is based on (among other things) the following assumptions: The Company has unrestricted cash at the closing of the Acquisition, net of our estimate of projected wind-down costs, of approximately $19 million."
• "Because our proposal includes an assumption about the amount of net unrestricted cash at the Acquisition closing, any delays to our consummating the Acquisition that result in a reduction in the amount of net unrestricted cash could in turn result in a reduction in our Acquisition price."
• "We are confident that we can complete our diligence review and related documentation on an expedited basis."
• "Because we have sufficient capital available to fund the Acquisition, our ability to secure financing will not delay our process and will not be a condition for us to close the Acquisition."
• "Disclosure by the Company or any of its directors, employees or advisors of the content of any discussions or negotiations related to this letter, or any other leaks, prior to execution of definitive acquisition agreements may result in our withdrawing our interest in the Acquisition."
• "We believe that this proposal represents a highly beneficial outcome for the Company and its stockholders and are excited by the potential benefits that the Acquisition would yield for all stakeholders."

Industry Context

Lynx1 Capital Management LP is a multi-stage investment firm focused on biotechnology, life sciences, and medical technology, with deep scientific expertise in neuroscience. This specialization aligns with Neuphoria Therapeutics Inc.'s operations, suggesting Lynx1's proposal is driven by a strategic understanding of the Company's sector and potential value within the therapeutic mechanisms space.

Comparison to Industry Standards

• The proposed 27% premium over Neuphoria's last closing price is a significant offer, generally considered attractive in M&A transactions, especially for a non-binding initial proposal.
• The offer price of $5.20 per share is above the weighted average exercise price of $5.11 for outstanding stock options, suggesting a positive outcome for option holders if the deal closes at this price or higher.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant positive impact due to the proposed acquisition at a substantial premium, offering an opportunity for liquidity and capital gains.
• Management and Employees: Potential for changes in leadership, corporate strategy, and employment status if the acquisition is completed.
• Board of Directors: Will need to evaluate the proposal and act in the best interest of shareholders, potentially engaging in negotiations or considering alternative strategies.
• Creditors: The all-cash nature of the proposal and assumptions about cash on the balance sheet suggest a stable financial transition, but specific impacts would depend on the final deal structure.

Next Steps

• Neuphoria's Board of Directors is expected to consider the proposal and respond by November 13, 2025, 12:00 p.m. (noon) New York time.
• Lynx1 intends to engage in discussions with Neuphoria regarding the terms of the Proposed Transaction.
• Lynx1 and its advisors are prepared to conduct due diligence and negotiate definitive agreements.
• Lynx1 may engage in discussions with other stockholders, potential sources of financing, advisors, and other relevant parties.
• Lynx1 may enter into confidentiality arrangements, financing commitments, and other agreements in connection with the Proposed Transaction.
• The Company's annual meeting of stockholders is scheduled for December 9, 2025, where Lynx1's nominated directors will be considered.

Key Dates

Recommendation

The non-binding acquisition proposal at a 27% premium is highly attractive, but its non-binding nature and the explicit risk of withdrawal or price reduction due to delays warrant caution. Investors should hold to monitor developments, including the Board's response, further negotiations, and any definitive agreements. A 'buy' recommendation would be premature given the uncertainties, while a 'sell' would forgo potential further upside if the deal progresses or a higher offer emerges.

Keywords

acquisition proposal, tender offer, shareholder activism, biotechnology, life sciences, corporate governance, board nomination, cash offer, premium, Neuphoria Therapeutics